The antimalarial ferroquine is an inhibitor of hepatitis C virus.

@article{Vausselin2013TheAF,
  title={The antimalarial ferroquine is an inhibitor of hepatitis C virus.},
  author={Thibaut Vausselin and No{\'e}mie Calland and Sandrine Belouzard and V{\'e}ronique Descamps and Florian Douam and Francois Helle and Catherine François and Dimitri Lavillette and Gilles Duverlie and Ahmed Wahid and Lucie F{\'e}n{\'e}ant and Laurence Cocquerel and Yann Gu{\'e}rardel and Czeslaw Wychowski and Christophe Biot and Jean Dubuisson},
  journal={Hepatology},
  year={2013},
  volume={58 1},
  pages={86-97}
}
UNLABELLED Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report that ferroquine (FQ), an antimalarial ferrocenic analog of chloroquine, is a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines by affecting an early step of the viral life cycle. The antiviral activity of FQ on HCV entry was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS